Filing Details

Accession Number:
0000899140-22-000356
Form Type:
13G Filing
Publication Date:
2022-02-16 19:00:00
Filed By:
Malnik Dov
Company:
Gri Bio Inc.
Filing Date:
2022-02-17
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Dov Malnik 509,781 0 509,781 0 509,781 7.5 %
Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.  )*


Vallon Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

92023M101
(CUSIP Number)



December 31, 2021
(Date of Event which Requires Filing
of this Statement)



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[   ]     Rule 13d-1(b)
[   ]     Rule 13d-1(c)
[X]     Rule 13d-1(d)



*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 92023M101
13G
Page 2 of 5   Pages
1
NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Dov Malnik
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)  ☐
(b)  ☐
 
3
SEC USE ONLY


4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Israel
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
509,781
6
SHARED VOTING POWER
 
0
7
SOLE DISPOSITIVE POWER
 
509,781
8
SHARED DISPOSITIVE POWER
 
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
509,781
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES                      ☐
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
7.5 %
12
TYPE OF REPORTING PERSON*
 
IN


Item 1(a)
Name of Issuer:
   
 
Vallon Pharmaceuticals, Inc. (the “Issuer”)
   
Item 1(b)
Address of Issuer's Principal Executive Offices:
   
   
 
100 N. 18th Street, Suite 300,
 
Philadelphia, PA 19103
   
Item 2(a)
Name of Person Filing:
   
 
The information required by Item 2(a) is set forth in Row 1 of the cover page hereto and is incorporated herein by reference.
   
   
Item 2(b)
Address of Principal Business Office or, if none, Residence:
 
8 Shlinka St.
 
Rishon le zion, 75451, Israel
   
   
Item 2(c)
Citizenship:
   
 
The information required by Item 2(c) is set forth in Row 4 of the cover page hereto and is incorporated herein by reference.
   
Item 2(d)
Title of Class of Securities:
   
 
Common Stock, $0.0001 par value per share (“Common Stock”)
   
Item 2(e)
CUSIP Number:
   
 
92023M101
   
Item 3
Statement filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c):
   
 
The information required by Item 3 is set forth in Row 12 of the cover page hereto and is incorporated herein by reference.
   
Item 4
Ownership:
   
 
The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page hereto and is incorporated herein by reference.
   
 
The ownership percentage disclosed in Row 11 of the cover page hereto is based on 6,812,836 outstanding shares of Common Stock, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.


Item 5
Ownership of Five Percent or Less of a Class:
   
 
Not Applicable
   
Item 6
Ownership of More than Five Percent on Behalf of Another Person:
   
 
Not Applicable
   
Item 7
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:
   
 
Not Applicable
   
Item 8
Identification and Classification of Members of the Group:
   
 
Not Applicable
   
Item 9
Notice of Dissolution of Group:
   
 
Not Applicable
   
Item 10
Certification:
   
 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

[Remainder of page intentionally left blank]

SIGNATURE

After reasonable inquiry and to the best of the knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated:  February 17, 2022

 
REPORTING PERSON
   
   
 
/s/ Dov Malnik                                          
 
Name:  Dov Malnik